Blood thinners during lung transplant bypass
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study compares two different blood thinners (UFH and LMWH) used during heart-lung bypass (ECMO) for double lung transplant patients. The goal is to see which one works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are having a double lung transplant and will be on a heart-lung bypass machine (VA-ECMO) during surgery.
- Your surgeon has already decided to use either standard blood thinner (UFH) or a different type (LMWH) during surgery.
- You are not currently on ECMO to keep you alive before the transplant.
- You do not need to stay on ECMO after the surgery.
- You do not have a known bleeding disorder, severe liver disease, or kidney failure on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
This study looks at using a heart–lung machine (ECMO) to reduce complications and deaths after a lung transplant. It focuses on people getting a lung transplant who have certain types of lung-vessel (pulmonary) pressure problems.
This trial studies whether people on a breathing machine called VV-ECMO can be managed without routine blood thinners, to reduce bleeding risk. It is meant for adults with severe lung failure (ARDS) and checks that it is safe for you to avoid anticoagulation.
This Phase 2 trial compares two blood-thinning medicines—bivalirudin and heparin—in people on ECMO (a machine that supports breathing and/or circulation). It aims to see which medicine works better and is safer while you are connected to the ECMO circuit.
This trial tests whether low doses of two blood thinners (argatroban and enoxaparin) can safely prevent clots in patients on ECMO life support. It aims to find a safer way to manage anticoagulation.
This study compares two ways of supporting the lungs and heart around the time of a double lung transplant: venoarterial ECMO versus an off-pump approach. It may help your team choose the safest support method based on your heart-lung pressures and surgical plan.
Hear when a new Lung Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.